A Phase 2 study to evaluate the efficacy and safety of DR10624 in participants with severe hypertriglyceridaemia (NCT06555640)

Please login or create a FREE account to view this content

Educational partners and supporters

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Ionis Logo

Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc. Kowa Logo